The original version of this article appeared in J Mol Med 88(7): [729][730][731][732][733][734][735][736][737][738][739][740] The authors have informed the Editors that there turns out to be some confusion about the identity of one of the three pancreatic tumor cell lines used in their study. A recently and carefully performed Short Tandem Repeats (STR) analysis of the pancreatic tumor cell lines used in their laboratory revealed that the batch of the pancreatic cancer cell line PT45 analyzed in this study is genetically identical to the wellknown mammary cancer cell line MDA-MB-231 (the results of the STR analysis can be provided by the authors upon request). Thus, the experimental results on the presumptive "PT45" cell line have to be regarded in terms of this limitation.
The original version of this article appeared in J Mol Med 88(7): [729] [730] [731] [732] [733] [734] [735] [736] [737] [738] [739] [740] The authors have informed the Editors that there turns out to be some confusion about the identity of one of the three pancreatic tumor cell lines used in their study. A recently and carefully performed Short Tandem Repeats (STR) analysis of the pancreatic tumor cell lines used in their laboratory revealed that the batch of the pancreatic cancer cell line PT45 analyzed in this study is genetically identical to the wellknown mammary cancer cell line MDA-MB-231 (the results of the STR analysis can be provided by the authors upon request). Thus, the experimental results on the presumptive "PT45" cell line have to be regarded in terms of this limitation.
Nonetheless, this error does not affect the general message and conclusions of this study since the other two pancreatic tumor cell lines investigated (Panc89 and Colo357) clearly demonstrate the findings reported by the authors. The authors confirm that the identity of these two cell lines was verified using the same STR analysis technique. Moreover, a subsequent article which appeared online in October 2010 (Stadel et al., 2010, Clin Cancer Res 16:5734-5749) came to the same conclusion.
The authors deeply regret this mistake and the confusion it might cause, since these "PT45" cells may also have been used by other groups.
